

# Thomas J Esparza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6505660/publications.pdf>

Version: 2024-02-01

29  
papers

2,013  
citations

361413

20  
h-index

552781

26  
g-index

32  
all docs

32  
docs citations

32  
times ranked

3691  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19. <i>MABs</i> , 2022, 14, 2047144.	5.2	10
2	Single-Domain Antibodies for the Detection of SARS-CoV-2 Nucleocapsid Protein. <i>Analytical Chemistry</i> , 2021, 93, 7283-7291.	6.5	30
3	Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8695.	4.1	8
4	Unbiased high-content screening reveals A $\beta$ <sup>2</sup> - and tau-independent synaptotoxic activities in human brain homogenates from Alzheimer's patients and high-pathology controls. <i>PLoS ONE</i> , 2021, 16, e0259335.	2.5	2
5	High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. <i>Scientific Reports</i> , 2020, 10, 22370.	3.3	95
6	Live Neuron High-Content Screening Reveals Synaptotoxic Activity in Alzheimer Mouse Model Homogenates. <i>Scientific Reports</i> , 2020, 10, 3412.	3.3	8
7	Repetitive Concussive and Subconcussive Injury in a Human Tau Mouse Model Results in Chronic Cognitive Dysfunction and Disruption of White Matter Tracts, But Not Tau Pathology. <i>Journal of Neurotrauma</i> , 2019, 36, 735-755.	3.4	19
8	Prospective natural history study of <i>C9orf72</i> ALS clinical characteristics and biomarkers. <i>Neurology</i> , 2019, 93, e1605-e1617.	1.1	29
9	Soluble amyloid-beta buffering by plaques in Alzheimer disease dementia versus high-pathology controls. <i>PLoS ONE</i> , 2018, 13, e0200251.	2.5	9
10	Disease-Modifying Effects of M <sub>1</sub> Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1177-1187.	3.5	36
11	Polarity of varicosity initiation in central neuron mechanosensation. <i>Journal of Cell Biology</i> , 2017, 216, 2179-2199.	5.2	44
12	Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. <i>Scientific Reports</i> , 2017, 7, 9520.	3.3	125
13	[P2068]: SOLUBLE AMYLOID $\beta$ AGGREGATES FROM HUMAN ALZHEIMER'S DISEASE BRAINS. <i>Alzheimer's and Dementia</i> , 2017, 13, P631.	0.8	0
14	Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of $\beta$ -amyloidosis. <i>Neuron</i> , 2017, 96, 1013-1023.e4.	8.1	134
15	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 62.	6.2	62
16	Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. <i>Scientific Reports</i> , 2016, 6, 38187.	3.3	119
17	P1099: Purification and Quantitative Characterization of Amyloid $\beta$ Oligomers from Alzheimer's Disease Brain Lysates. <i>Alzheimer's and Dementia</i> , 2016, 12, P439.	0.8	0
18	P1100: Amyloid $\beta$ (A $\beta$ ) Isoforms and P <sub>ts</sub> of Soluble A $\beta$ Oligomers from Human Brain. <i>Alzheimer's and Dementia</i> , 2016, 12, P439.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Quantitative assessments of traumatic axonal injury in human brain: concordance of microdialysis and advanced MRI. <i>Brain</i> , 2015, 138, 2263-2277.	7.6	45
20	Amyloid $\beta$ oligomerization in Alzheimer dementia versus high $\beta$ pathology controls. <i>Annals of Neurology</i> , 2013, 73, 104-119.	5.3	244
21	Human Apolipoprotein E4 Worsens Acute Axonal Pathology but Not Amyloid- $\beta$ Immunoreactivity After Traumatic Brain Injury in 3 $\beta$ -TG-AD Mice. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 396-403.	1.7	36
22	Tau elevations in the brain extracellular space correlate with reduced amyloid- $\beta$ levels and predict adverse clinical outcomes after severe traumatic brain injury. <i>Brain</i> , 2012, 135, 1268-1280.	7.6	150
23	Distinct Temporal and Anatomical Distributions of Amyloid- $\beta$ and Tau Abnormalities following Controlled Cortical Impact in Transgenic Mice. <i>PLoS ONE</i> , 2011, 6, e25475.	2.5	80
24	Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. <i>Journal of Neural Transmission</i> , 2010, 117, 85-96.	2.8	87
25	Traumatic brain injury reduces soluble extracellular amyloid- $\beta$ in mice: A methodologically novel combined microdialysis-controlled cortical impact study. <i>Neurobiology of Disease</i> , 2010, 40, 555-564.	4.4	48
26	Amyloid- $\beta$ Dynamics Correlate with Neurological Status in the Injured Human Brain. <i>Science</i> , 2008, 321, 1221-1224.	12.6	270
27	Activation of Type B T Cells after Protein Immunization Reveals Novel Pathways of In Vivo Presentation of Peptides. <i>Journal of Immunology</i> , 2007, 178, 122-133.	0.8	22
28	Immunological Reversal of Autoimmune Diabetes Without Hematopoietic Replacement of $\beta$ Cells. <i>Science</i> , 2006, 311, 1778-1780.	12.6	103
29	Molecular and Biochemical Characterization of a Cytokinin Oxidase from Maize. <i>Plant Physiology</i> , 2001, 125, 378-386.	4.8	195